Trial Profile
Safety, Tolerability and Biomarker Assessments of Leukine (Sargramostim) During Extended Timed Treatment for Parkinson's Disease: A Phase I Pilot Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Sargramostim (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- 14 Nov 2023 Planned primary completion date changed from 30 Oct 2023 to 30 Oct 2024.
- 19 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 19 Oct 2022 Planned End Date changed from 30 Sep 2022 to 30 Dec 2024.